AIMTo study the pharmacokinetics and relative bioavailability of probucol inclusion complex capsule.

METHODSFollowing oral administration of a single dose of 250 mg of conventional tablet (formulation A, purchased from the market) and probucol inclusion complex capsule (formulation B, a new formulation for preclinical trial) to each of 6 healthy dogs in a randomized crossover design, the plasma levels of the active drug at different time points were determined by HPLC and the plasma concentration-time profiles of formulation A and B were obtained. The pharmacokinetic parameters as well as relative bioavailability were analyzed.

RESULTSThe concentration-time curves of formulation A and formulation B were found to fit a two-compartment open model. The Tmax values of formulation A and formulation B were (9.3 +/- 2.1) h and (9.3 +/- 2.1) h, the Cmax values were (1.5 +/- 1.0) microgram.mL-1 and (2.3 +/- 0.9) microgram.mL-1 and the AUC0-240 values were (85 +/- 56) microgram.h.mL-1 and (134 +/- 55) microgram.h.mL-1, respectively. The relative bioavailability of formulation B was found to be (198 +/- 90)% compared with formulation A. The results of variance analysis and two one-side t-test showed that there was significant difference between the two formulations in the AUC0-240.

CONCLUSIONThe high bioavailability by the inclusion of formulation B is attributed to the improvement of its water-solubility by the inclusion process and this is supposed to be a key factor for improving drug bioavailability.

Administration, Oral ; Animals ; Anticholesteremic Agents ; administration & dosage ; pharmacokinetics ; Biological Availability ; Capsules ; Dogs ; Female ; Probucol ; administration & dosage ; pharmacokinetics ; Random Allocation ; Tablets

PURPOSE: In adriamycin(ADR)-induced cardiomyopathy, several different mechanisms are suggested. However, little information is available regarding the role of apoptosis. In the present study, we examined the induction of apoptosis on ADR treatment and anti-apoptotic effects of probucol, a lipid-lowering drug, and we also studied the changes of bcl-2 expression in order to see the molecular mechanisms underlying the effect of probucol. METHODS: Cardiac myocytes were isolated from 3-day-old rats, and cultured in low(1 pM) or high doses(10pM) of ADR for 24 hours. Probucol(50 pM) was added 30 minutes before ADR administration. Apoptosis was determined by TUNEL staining, and bcl-2 expression was estimated by immunocytochemistry. RESULTS: The number of TUNEL-positive cells significantly increased in both groups treated with ADR. However, anti-apoptotic effect of probucol was evident only in low dose. In addition, the expression of bcl-2 was significantly increased only in the low-dose ADR treatment group and its expression was inhibited by pretreatment of probucol. CONCLUSION: These results suggest that apoptosis might play an important role in ADR-induced cardiotoxicity, and ADR-induced apoptosis was partially prevented by pretreatment of probucol. And ADR-induced apoptosis was not related with depression of bcl-2. Additionally, inhibition of bcl-2 gene expression of low-dose ADR treatment group by probucol suggests that another cell survival mechanism could be implicated in the action of probucol. (J Korean Pediatr Soc 2000;43:746-754)
Animals ; Apoptosis* ; Cardiomyopathies ; Cell Survival ; Depression ; Doxorubicin ; Genes, bcl-2 ; Immunohistochemistry ; In Situ Nick-End Labeling ; Myocytes, Cardiac* ; Probucol* ; Rats*

BACKGROUND AND OBJECTIVES: In a recent multicenter trial probucol was found to reduce stent restenosis by improving the lumen dimension. The probucol was administered for 2 weeks before, and 4 weeks after, stenting. The release of the drug at the site of a vascular injury, via polymer-coated stents, helps achieve an effective local concentration. The feasibility of a probucol stent coating in reducing in-stent restenosis was assessed. MATERIALS AND METHODS: The probucol loading and in vitro release were assessed using BiodivYsioTM stents, in a 50 mg/mL probucol solution. After being dip-coated with probucol (n=8), or a control (n=8) solution, the stents were implanted in 8 pigs. Angiography and histopathological analyses were performed 28 days later. RESULTS: The total probucol loading was 52+/-16 microgram/stent, with no release for up to 72 hours after loading. No pig died until sacrifice. On angiography, the reference and minimum lumen diameters showed no significant differences between the two groups, with similar diameters stenosis (8.7+/-3.68 vs. 13.3+/-4.18%, p=0.120). On histomorphometry, the injury scores, vessel, lumen and neointimal areas showed no significant differences between the groups, with similar areas of stenosis (23.1+/-12.39 vs. 25.2+/-8.22%, p=0.671). The degrees of re-endothelialization, inflammation and smooth muscle cell proliferation were not significantly different. CONCLUSIONS: Probucol can be loaded onto a polymer-coated stent, and does not release from the stent for up to 72 hours after loading. About 52 microgram probucol per stent does not reduce in-stent restenosis in porcine coronary arteries.
Angiography ; Antioxidants ; Constriction, Pathologic ; Coronary Disease ; Coronary Vessels ; Inflammation ; Myocytes, Smooth Muscle ; Probucol ; Stents* ; Swine ; Vascular System Injuries

BACKGROUND: AGE-induced oxidative stress is implicated in the development and progression of diabetic nephropathy. AGE also affect the GEC to increase their permeability, therefore, we investigate the possibility that AGE may induce oxidative stress and subsequent injury to GEC. METHODS: We cultured rat GEC on the AGE- or BSA-coated plate with high glucose (HG) to produce more pathophysiologic conditions similar to prolonged diabetic environment in vivo and measured the change of ROS and their anti-oxidants systems. We also evaluated the effects of probucol as an antioxidant on this system. RESULTS: The amount of superoxide anion slightly decreased on AGE condition without significance. However, the production of hydrogen peroxide was significantly enhanced by 10% on AGE-coated and HG condition compared to control (BSA-coated and 5 mM glucose) (p< 0.05) and hydroxyl radical have also showed similar increase on AGE-coated and HG condition by 10% above control (p< 0.01), and both increases were attenuated by probucol (both, p< 0.05). The activity of superoxide dismutase (SOD) was decreased by 10% on AGE-coated and HG condition (p< 0.05) and recovered by probucol partially. However, there were no significant changes on the activity of other anti-oxidant enzymes including catalase, glutathione peroxidase, and glutathione reductase. Therefore, glomerular epithelial injury presenting proteinuria may be provoked by hydrogen peroxide and subsequently increased hydroxyl radical induced by AGE and high glucose. CONCLUSION: We might assume that superoxide had been converted to hydrogen peroxide by consumptive SOD in the presence of AGE, and subsequently produced hydroxyl radical, which could be reversed by anti-oxidant, may induce diabetic glomerular epithelial injury and eventually proteinuria.
Animals ; Catalase ; Diabetic Nephropathies ; Epithelial Cells* ; Glucose ; Glutathione Peroxidase ; Glutathione Reductase ; Hydrogen Peroxide ; Hydroxyl Radical ; Oxidative Stress ; Permeability ; Probucol ; Proteinuria ; Rats* ; Reactive Oxygen Species* ; Superoxide Dismutase ; Superoxides

Apolipoprotein (apo) E deficient mouse can produce reproducible fixed stenotic primary atherosclerotic lesion, which reveals failure to remodel of vascular lumen, in the ascending aorta, external carotid, common carotid, iliac, femoral and popliteal arteries. To evaluate the effect of drugs in regarding to both prevention of primary atherosclerotic lesion and vascular remodeling, a systematic analysis of distribution of atherosclerotic lesions was undertaken in chow-fed, 9-momth-old apo E deficient mice, which was administrated drugs including asprin, methotrexate, probucol, sulodexide, diltiazem, cilazapril, trimetazidine, molsidomine, pentoxiphylline and Ginexin (R) for 7 month from 3 month-old. On gross and microscopic examination, formation of primary atheroscleotic lesions could be delated and/or prevented patially by effets of these drugs. On morphometric examination, failure to remodel forming vascular stenosis could not be seen, though relatively mild atherosclerotic lesion occured at vascular tree. These data suggest that the stenotic process in advanced atherosclerotic vessels can be delayed and/or prevented by several drugs including methotrexate, probucol, sulodexide, diltiazem, cilazapril, trimetazidine, molsidomine, pentoxiphylline and Ginexin (R) in vivo state.
Animals ; Aorta ; Apolipoproteins ; Apolipoproteins E* ; Atherosclerosis ; Cilazapril ; Constriction, Pathologic ; Diltiazem ; Humans ; Infant ; Methotrexate ; Mice ; Mice, Knockout* ; Molsidomine ; Popliteal Artery ; Primary Prevention ; Probucol ; Trimetazidine

OBJECTIVEContrast induced acute kidney injury (CIAKI) is a significant clinical problem. We, therefore, performed a prospective, randomized trial to investigate the role of probucol in the prevention of CIAKI in patients with unstable angina pectoris (UAP) undergoing percutaneous coronary angiography (CAG) and interventions (PCI).

METHODSWe studied 205 patients with UAP, who underwent CAG or PCI prospectively. Patients were randomly assigned to probucol group (n = 102) and control group (n = 103). In the probucol group, the patients received probucol tablets 500 mg b.i.d for 3 days before and after intervention. All the patients, after intervention, underwent hydration with intravenous saline at a rate of 1 ml per kilogram of body weight per hour for 12 hours.

RESULTSPatients were well-matched with no significant difference at baseline in majority measured parameters between two groups. CIAKI occurred in 23 of the 205 (11.22%) patients. Multivariate logistic regression was used to identify correlates of CIAKI and clinical data. CIAKI was most strongly associated with Scr > or = 132.6 micromol/L (OR = 21.11, 95%CI 1.95 - 56.06, P < 0.001), Ccr < 60 ml/min (OR = 4.19, 95%CI 1.94 - 9.05, P < 0.001), heart function > class II (OR = 6.23, 95%CI 2.73 - 14.21, P < 0.001), Diabetes (OR = 2.049, 95%CI 1.19 - 5.25, P < 0.001), age > or = 70 yrs (OR = 3.52, 95%CI 1.66 - 7.43, P < 0.001), coronary artery calcification shown by CAG (OR = 4.29, 95%CI 1.99 - 9.24, P < 0.001). The rate of CIAKI in probucol groups was slightly lower compared with control group (7.84% vs. 14.56%), without significant difference. The post-procedure mean peak of Scr [(101.62 +/- 42.98) micromol/L vs. (117.67 +/- 68.77) micromol/L, P = 0.047] and the post-procedure increasing Scr from baseline (DeltaScr) [(13.49 +/- 19.61) micromol/L vs. (22.50 +/- 18.31) micromol/L, P = 0.001] in the probucol group decreased significantly compared with that of control group.

CONCLUSIONProphylactic treatment with probucol 500 mg b.i.d during periprocedural stage in patients with UAP has preventing role against CIAKI after cardiac catheterization.

Acute Kidney Injury ; chemically induced ; prevention & control ; Aged ; Angina, Unstable ; diagnostic imaging ; Contrast Media ; adverse effects ; Coronary Angiography ; Female ; Humans ; Male ; Middle Aged ; Probucol ; therapeutic use ; Prospective Studies

BACKGROUND: Tranilast is an anti-allergic drug that suppresses the release of cytokines. An antioxidant, probucol, prevents endothelial dysfunction and oxidation of low density lipoprotein and also inhibits the secretion of interleukin-1 by macrophages. In several studies, both the tranilast and probucol with multivitamins have been shown to decrease the frequency of angiographic restenosis after PCI. METHODS: We analyzed clinical events and restenosis at 6 months following percutaneous coronary angioplasty in 93 patients with 113 coronary arterial lesions after coronary stenting at Soonchunhyang University Hospital between Jan 2001 and Apr 2003. The patients were assigned to following three groups: 39 patients who didn't receive tranilast and antioxidants (control group, M 29, F 10, 61 +/- 10 years) ; 25 patients who received probucol (500 mg), vitamin C (1,000 mg), vitamin E (400 mg) (antioxidant group, M 19, F 6, 62 +/- 10 years) ; 29 patients who received tranilast (400 mg) (Tranilast group, M 18, F 11, 59 +/- 9 years). RESULTS: The restenosis per lesion between three groups was not different significantly (control group, 32.7%; antioxidant group, 26.7%; Tranilast group, 20.6%). At follow-up, minimal luminal diameter (MLD) was not different significantly between three groups (control group, 1.8 +/- 1.07 mm; antioxidant group, 2.1 +/- 1.18 mm; Tranilast group, 2.1 +/- 0.94 mm). Target lesion revascularization was lower in Tranilast group (3.4%) as compared with control group (25.6%) and antioxidant group (16%, p<0.05). CONCLUSION: Neither probucol combined with vitamin C and E nor tranilast did not improve significantly the angiographic restenosis rate. But tranilast had reduced the target lesion revascularization rate as compared with control group and antioxidant group.
Angioplasty ; Antioxidants ; Ascorbic Acid ; Cytokines ; Follow-Up Studies ; Humans ; Interleukin-1 ; Lipoproteins ; Macrophages ; Percutaneous Coronary Intervention* ; Phenobarbital ; Probucol* ; Stents ; Vitamin E ; Vitamins

BACKGROUND: Oxidative stress might be a role in atherosclerosis and increased intake of antioxidant appear to be protective and modify neointimal formation. An antioxidant and probucol prevents endothelial dysfunction and low density lipoprotein oxidation and also inhibits the secretion of cytokine by macrophages. We aimed 1) to study the effects of antioxidant (Vitamin C, E and probucol) supplementation on serum level of antioxidant status (TAS), P-selectin, MCP-1, IL-6 and IL-10 and 2) to investigate the effects of antioxidant intake on in-stent restenosis. METHODS: Total 90 patients were assigned to control or antioxidant group (probucol; 500 mg, vitamin C; 1,000 mg, vitamin E; 400 mg). We performed follow up coronary angiography in 35 patients of antioxidant group and 36 patients of control group after 6 months of coronary bare metal stent implantation. We counted the stenotic lesions more than 50% of implanted stent lumen as a restenosis by quantitative coronary angiography. The serum levels of total antioxidant status, P-selectin, MCP-1, IL-6 and IL-10 were measured. RESULTS: The serum levels of total antioxidant status was not elevated in antioxidant group. Antioxidant supplementation did not change the serum levels of P-selectin, MCP-1, IL-6 and IL-10. The 6-month angiographic in-stent restenosis rate was 27% versus 30% (p=NS) with an associated late loss of 0.76+/-1.01 mm versus 0.91+/-1.00 mm (p=NS) for antioxidant group and control group. The serum levels of total antioxidant status did not correlate with the restenosis or late loss after stent implantation. CONCLUSIONS: Vitamin C, E and probucol did not elevate the serum level of antioxidant status and could not prevent in-stent restenosis after bare metal stent implantation.
Antioxidants ; Ascorbic Acid ; Atherosclerosis ; Coronary Angiography ; Coronary Restenosis ; Cytokines ; Follow-Up Studies ; Humans ; Interleukin-10 ; Interleukin-6 ; Lipoproteins ; Macrophages ; Oxidative Stress ; P-Selectin ; Probucol ; Stents ; Vitamin E ; Vitamins

OBJECTIVETo determine the effects of probucol on serum parameters and liver histopathology in rats with non-alcoholic steatohepatitis (NASH) and explore the mechanisms.

METHODSForty male Sprague-Dawley rats were randomly assigned into 4 equal groups, namely the normal control group (NC group) with a standard feeding, high-fat diet group (HD group) fed with a high-fat diet, probucol (500 mg/kg daily) control group (NP group) fed with standard diet, and probucol group fed with a high-fat diet (HP group). After 15 weeks of feeding, the rats were euthanized for histopathological inspection of the liver with HE staining and detection of farnesoid X receptor (FXR), SHP and SREBP-1C expressions using semi-quantitative RT-PCR and Western blotting.

RESULTSAfter the 15-week feeding, the rats in HP group had significantly lower levels of serum ALT, AST, cholesterol, bile acid, and free fatty acid than those in HD group (P<0.01 or 0.05). Compared with the normal control group, high-fat diet feeding resulted in significantly decreased mRNA and protein levels of FXR and SHP (P<0.05) and significantly increased SREBP-1C level (P<0.05). These high-fat diet-induced gene expression changes were reversed by probucol intervention (P<0.05).

CONCLUSIONProbucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH possibly by up-regulating FXR expression.

Animals ; Anticholesteremic Agents ; pharmacology ; Diet, High-Fat ; Disease Models, Animal ; Male ; Non-alcoholic Fatty Liver Disease ; blood ; drug therapy ; Probucol ; pharmacology ; RNA, Messenger ; Rats ; Rats, Sprague-Dawley

BACKGROUND: Doxorubicin is considered to be one of the most effective drugs to treat a variety of human cancers. However, the dose-dependent cardiotoxicity of doxorubicin limits its clinical usefulness. This study aimed to evaluate the effect of probucol and verapamil on the cardiac neurotoxicity and cardiomyopathy induced by the long-term use of doxorubicin. METHODS: Sprague-Dawley male rats were grouped as the control group, the doxorubicin treated group, the doxorubicin treated with probucol group, and the doxorubicin treated with verapamil group. The rats were treated for 4, 6, 8 and 10 weeks. H&E staining and immunohistochemical staining for protein gene product 9.5, caspase-3, heat shock protein 70, and hsp 25 were performed. RESULTS: The degree of interstitial inflammatory cell infiltration was mildest in the probucol treated group. The reduction in the number of nerve fibers in the probucol treated group was less than the other treatment groups. There was a negative correlation between the treatment duration and stained nerve fibers in all the treatment groups. The number of caspase-3 positive cells was more increased in the doxorubicin group and the verapamil treated group than in the control and probucol treated group. CONCLUSION: It is suggested that probucol partly contributed to the inhibition of doxorubicin-induced cardiac neurotoxicity and cardiomyopathy, whereas the verapamil had no effect.
Animals ; Cardiomyopathies ; Caspase 3 ; Doxorubicin* ; Heart* ; HSP70 Heat-Shock Proteins ; Humans ; Male ; Myocardium* ; Nerve Fibers* ; Probucol* ; Rats* ; Rats, Sprague-Dawley ; Verapamil*